GlassScriptPhysician profile
Ayarpi Nikolopoulos
NPI 1841332376
$10,292.35
in general payments reported to CMS, 2019-2025
58 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,147 · 2022: $3,703 · 2023: $2,968 · 2024: $275 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.28 |
| Education | $212.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $919.07 | 2021-2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $579.24 | 2021-2023 | Imbruvica, Darzalex, Erleada |
| Genzyme Corporation | $557.76 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $532.55 | 2021-2024 | Enhertu, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $483.16 | 2021-2023 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $451.73 | 2021-2023 | Xpovio |
| Celgene Corporation | $432.41 | 2021-2023 | Opdualag, Reblozyl |
| Astellas Pharma US INC | $378.48 | 2021-2024 | Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $366.16 | 2021-2023 | |
| Seagen INC. | $357.50 | 2021-2023 | Adcetris, Padcev |
| Pfizer INC. | $345.88 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $330.63 | 2021-2023 | |
| Blueprint Medicines Corporation | $301.04 | 2021-2023 | Ayvakit |
| Amgen INC. | $258.38 | 2022-2023 | Lumakras, Kyprolis |
| Gilead Sciences, INC. | $243.25 | 2021-2023 | Trodelvy |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $225.66 | 2021-2023 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $213.87 | 2021-2023 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $202.00 | 2021-2023 | Iclusig, Ninlaro |
| Genentech USA, INC. | $197.28 | 2021-2023 | Venclexta, Phesgo, Polivy |
| Eisai INC. | $190.16 | 2021-2023 | |
| Tersera Therapeutics LLC | $188.06 | 2021-2023 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.09 | 2021-2023 | Gilotrif |
| Exelixis INC. | $163.27 | 2021-2023 | Cabometyx |
| Daiichi Sankyo INC. | $144.71 | 2021-2023 | Enhertu |
| Pharmaessentia USA Corporation | $126.50 | 2022-2023 | Besremi |
| Puma Biotechnology, INC. | $125.16 | 2021-2023 | Nerlynx |
| Alexion Pharmaceuticals, INC. | $119.20 | 2021-2022 | |
| Abbvie INC. | $114.28 | 2021-2023 | |
| Tolmar Pharmaceuticals, INC. | $106.49 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $104.65 | 2021-2023 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $95.87 | 2021-2022 | |
| Array Biopharma INC | $95.59 | 2022-2023 | Braftovi, Lorbrena, Xalkori |
| Glaxosmithkline, LLC. | $91.14 | 2021-2023 | Jemperli, Zejula |
| Sobi, INC | $89.02 | 2022-2023 | |
| Kite Pharma, INC. | $79.65 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $78.95 | 2021-2023 | |
| Taiho Oncology, INC. | $75.93 | 2021-2023 | |
| Stemline Therapeutics INC. | $69.63 | 2023 | Orserdu |
| Dova Pharmaceuticals | $68.17 | 2021 | |
| Novocure INC. | $68.13 | 2021-2025 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $59.90 | 2021 | |
| Organon LLC | $59.84 | 2021-2023 | Ontruzant |
| Morphosys, US INC. | $40.29 | 2022-2023 | Monjuvi |
| Chiesi USA, INC. | $37.35 | 2022-2023 | Ferriprox |
| Acrotech Biopharma INC. | $34.66 | 2021 | |
| Caris Mpi, INC. | $34.64 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $28.42 | 2023 | |
| Immunogen, INC. | $26.34 | 2023 | Elahere |
| Global Blood Therapeutics, INC. | $24.19 | 2021 | |
| Clovis Oncology, INC. | $23.65 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.55 | 2022 | |
| Beigene USA, INC. | $23.18 | 2022 | |
| Acceleron Pharma, INC. | $22.97 | 2021 | |
| Boston Scientific Corporation | $20.69 | 2021 | |
| Deciphera Pharmaceuticals INC. | $20.43 | 2023 | Qinlock |
| Mirati Therapeutics, INC. | $20.01 | 2023 | Krazati |
| Ge Healthcare | $19.29 | 2022 | |
| Adc Therapeutics America, INC. | $16.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayarpi Nikolopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.